Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 31 - Medicinal preparations containing organic active ingredients
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
10/2012
10/18/2012WO2012140133A1 Nutritional compositions including branched chain fatty acids and methods of using same
10/18/2012WO2012140132A1 Nutritional compositions including branched chain fatty acids for improving gut barrier function
10/18/2012WO2012140118A1 Nutritional compositions including branched chain fatty acids for wound healing
10/18/2012WO2012140114A1 Tri- and tetracyclic pyrazolo[3,4-b]pyridine compounds as antineoplastic agent
10/18/2012WO2012140095A1 Peptidyl arginine deiminase 1 and/or 3 activator compounds in the epidermis and uses thereof
10/18/2012WO2012140081A1 Aclidinium for use in improving the quality of sleep in respiratory patients
10/18/2012WO2012140020A1 Novel piperidinyl monocarboxylic acids as s1p1 receptor agonists
10/18/2012WO2012139993A1 1,3 oxazines as bace1 and/or bace2 inhibitors
10/18/2012WO2012139963A1 N- cyclobutyl - imidazopyridine - methylamine as trpv1 antagonists
10/18/2012WO2012139930A1 Pyrazolyl-pyrimidine derivatives as kinase inhibitors
10/18/2012WO2012139925A1 Labelled and un-labelled methyl-pyrrolyl-oxadiazolyl-diazabicyclononane derivatives and their medical use
10/18/2012WO2012139918A1 Methods for treating bacterial infection
10/18/2012WO2012139895A1 Process for the manufacture of a powder containing lutein
10/18/2012WO2012139888A1 Branched 3-phenylpropionic acid derivatives and the use thereof
10/18/2012WO2012139876A1 Enteric formulations of metabotropic glutamate receptor modulators
10/18/2012WO2012139775A1 Pyrrolo sulfonamide compounds for modulation of orphan nuclear receptor rar-related orphan receptor-gamma (rorgamma, nr1f3) activity and for the treatment of chronic inflammatory and autoimmune diseases
10/18/2012WO2012139628A1 Coding polypurine hairpins for the treatment of cancer
10/18/2012WO2012139529A1 D-amino acid oxidase inhibitor for preventing and/or reversing opioid tolerance
10/18/2012WO2012139524A1 Cb1 receptor inhibitor with low toxicity and optical activity and preparation method and use thereof
10/18/2012WO2012139522A1 Dehydrocostus lactone derivative, pharmaceutical compositions thereof, preparation method therefor, and uses thereof
10/18/2012WO2012139507A1 Application of bisphenol fluorene and derivative thereof in preparing medicament for prophylaxis and treatment of cancer
10/18/2012WO2012139499A1 Urea compounds as well as preparation methods, intermediates and uses thereof
10/18/2012WO2012139495A1 Mineralocorticoid receptor antagonists
10/18/2012WO2012139487A1 Pegylated derivatives of camptothecin compounds
10/18/2012WO2012139485A1 Oral solid preparation of compound antituberculosis drug and preparation method thereof
10/18/2012WO2012139425A1 5-substituted iminothiazines and their mono-and dioxides as bace inhibitors,compositions,and their use
10/18/2012WO2012139424A1 Crystalline forms of tebipenem, preparation methods and uses thereof in the preparation of medicines
10/18/2012WO2012139422A1 Novel anti-platelet compound addition salt
10/18/2012WO2012139262A1 Sustained-release preparation of compound methoxyphenamine
10/18/2012WO2012139227A1 Use of s-adenosylmethionine, vitamin e, and vitamin c for the prevention and treatment of cardiovascular dysfunction
10/18/2012WO2012139212A1 Preparation and use of pseudopteroxazole and pseudopterosin analogs and derivatives
10/18/2012WO2012139191A1 Pharmaceutical compositions containing 11,12-pyrazole minocycline and use thereof for relieving pain of neuropathic origin
10/18/2012WO2012139190A1 Multilayered films for the controlled release of volatile substances adsorbed in a solid substrate, and use thereof
10/18/2012WO2012139164A1 Polymer conjugated prostaglandin analogues
10/18/2012WO2012115480A3 Diaminopyrimidine derivatives and processes for the preparation thereof
10/18/2012WO2012115478A3 Diaminopyrimidine derivatives and processes for the preparation thereof
10/18/2012WO2012115402A3 Crystalline form of docetaxel and process for preparation thereof
10/18/2012WO2012114285A9 Heteroaryl derivatives as alpha7 nachr modulators
10/18/2012WO2012113850A3 (PYRIDIN-4-YL)BENZYLAMIDES AS ALLOSTERIC MODULATORS OF ALPHA 7 nAChR
10/18/2012WO2012112447A9 Histone deacetylase inhibitors and methods of use thereof
10/18/2012WO2012111997A3 Cell therapy composition for preventing or treating immune disease comprising mesenchymal stem cells and immunoregulatory t-cells as active ingredient
10/18/2012WO2012111029A3 Ophthalmic composition for enabling dilation of pupils
10/18/2012WO2012109527A3 Class of hdac inhibitors expands the renal progenitor cells population and improves the rate of recovery from acute kidney injury
10/18/2012WO2012106702A3 Treatment of leukemia
10/18/2012WO2012103163A3 Compositions and methods for treating cancer while preventing or reducing cardiotoxicity and/or cardiomyopathy
10/18/2012WO2012103059A3 Bcl-2/bcl-xl inhibitors and therapeutic methods using the same
10/18/2012WO2012102875A3 Analgesic compounds, methods, and formulations
10/18/2012WO2012102560A3 Novel 4-0-methylhonokiol derivative and composition containing same as active ingredient for treatment of inflammatory diseases
10/18/2012WO2012102555A3 Fucoidan for thrombolysis, derived from seaweed
10/18/2012WO2012099375A3 P47phox or p67phox-targeting therapeutic agent for stress disorders, and method for screening for same
10/18/2012WO2012097978A3 Pharmaceutical compositions of immunosuppressants
10/18/2012WO2012097264A3 Pharmaceutical compositions for topical delivery of photosensitizers and uses thereof
10/18/2012WO2012096939A3 Highly concentrated liquid acetaminophen solutions
10/18/2012WO2012095388A3 Compounds for treatment of feline leukemia in felidae
10/18/2012WO2012093973A3 Compositions in the form of tablets comprising acarbose
10/18/2012WO2012091372A3 Caffeine tape for body slimming
10/18/2012WO2012078902A3 Proteostasis regulators
10/18/2012WO2012073214A4 Heptose derivatives for use in the treatment of bacterial infections
10/18/2012WO2011103460A8 Fused tetracyclic pyrido[4,3-b]indole and pyrido[3,4-b]indole derivatives and methods of use
10/18/2012US20120266263 Method of treating memory disorders and enhancing memory using igf-ii compounds
10/18/2012US20120265158 Transdermal Patch Formulation
10/18/2012US20120265119 Transdermal Delivery of Medicinal Cetylated Fatty Esters using Phonophoresis or Iontophoresis
10/18/2012US20120265001 Composite magnetic nanoparticle drug delivery system
10/18/2012US20120264999 4 (pyrrolopyridinyl)pyrimidin-2-ylamine derivatives
10/18/2012US20120264966 Sulfur-containing phospholipid derivatives
10/18/2012US20120264829 Method for administering an nmda receptor antagonist to a subject
10/18/2012US20120264828 Polymorphic forms of o-desmethyl-venlafaxine succinate
10/18/2012US20120264827 Sulfanylamide derivatives, uses thereof and compositions comprising them
10/18/2012US20120264826 N-Acetyl Beta Alanine Methods of Use
10/18/2012US20120264824 Compositions and methods for treating non-alcoholic steatohepatitis
10/18/2012US20120264823 Substituted heteroaryl- and aryl-cyclopropylamine acetamides and their use
10/18/2012US20120264822 Method of improving animal tissue quality by supplementing the animal diet with oleic acid and selected tocols
10/18/2012US20120264821 Use of equol for treating androgen mediated diseases
10/18/2012US20120264820 Synthetic Flavonoids and Pharmaceutical Compositions and Therapeutic Methods of Treatment of HIV infection and other pathologies
10/18/2012US20120264819 Therapeutic Uses of Urolithins
10/18/2012US20120264818 Topical Compositions with Cannabis Extracts
10/18/2012US20120264817 Solubilized formulation of docetaxel without tween 80
10/18/2012US20120264816 Sulfated Oxysterol and Oxysterol Sulfation by Hydroxysterol Sulfotransferase Promote Lipid Homeostasis and Liver Proliferation
10/18/2012US20120264815 Reversible platelet inhibition
10/18/2012US20120264813 siRNA Targeting Cyclin-dependent Kinase Inhibitor 1B (p27, Kip1) (CDKN1B)
10/18/2012US20120264812 Treatment of nuclear respiratory factor 1 (nrf1) related diseases by inhibition of natural antisense transcript to nrf1
10/18/2012US20120264811 Elongator Proteins and Use Thereof as DNA Demethylases
10/18/2012US20120264810 Compositions and methods for enhancing cellular uptake and intracellular delivery of lipid particles
10/18/2012US20120264809 RNAi-Mediated Inhibition of Histamine Receptor H1-Related Conditions
10/18/2012US20120264808 Methods and compositions for modulating calcium channels
10/18/2012US20120264807 Method for introducing sirna into cells by photochemical internalisation
10/18/2012US20120264806 Oligomeric compounds and excipients
10/18/2012US20120264805 Medicament for the treatment and prevention of liver failure
10/18/2012US20120264804 T type calcium channel blockers and the treatment of diseases
10/18/2012US20120264803 Method for predicting therapeutic effects of chemotherapy on hepatocellular carcinoma patients
10/18/2012US20120264802 Photosensitizers for targeted photodynamic therapy
10/18/2012US20120264801 5-membered heterocycle-based p38 kinase inhibitors
10/18/2012US20120264800 Kinase inhibitors and method of treating cancer
10/18/2012US20120264799 Indane-amine derivatives, their preparation and use as medicaments
10/18/2012US20120264798 Prodrugs of inhibitors of plasma kallikrein
10/18/2012US20120264797 Cannabinoid receptor antagonists/inverse agonists useful for treating metabolic disorders, including obesity and diabetes
10/18/2012US20120264796 Methods for modulating circadian rhythms
10/18/2012US20120264795 Combination therapy with parp inhibitors
10/18/2012US20120264794 Method for Preparing Largazole Analogs and Uses Thereof
10/18/2012US20120264793 Pharmaceutical Use of 2',2-Bis-Thiazole Non-Nucleoside Compounds as Hepatitis C Virus Inhibitor
1 ... 993 994 995 996 997 998 999 1000 1001 1002 1003 1004 1005 1006 1007 1008 1009 1010 1011 1012 1013 ... 7860